Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-10 00:36 | 2025-12-05 | MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | LUCIER GREGORY T | Director | BUY | $3.69 | 100,000 | $368,540 | 155,123 |
| 2025-12-10 02:04 | 2025-12-05 | ARWR | Arrowhead Pharmaceuticals Inc. | PERRY MICHAEL S | Director | SELL | $61.03 | 16,250 | $991,738 | 115,240 |
| 2025-12-10 01:25 | 2025-12-05 | JAZZ | Jazz Pharmaceuticals plc | Carr Patricia | Officer | OPT+S | $171.20 | 4,660 | $797,783 | 7,012 |
| 2025-12-10 04:00 | 2025-08-21 | GNLX | GENELUX Corp | Smalling Ralph | Officer | SELL | $3.75 | 2,332 | $8,740 | 68,658 |
| 2025-12-10 01:07 | 2025-12-05 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $1.00 | 95,179 | $94,789 | 2,973,099 |
| 2025-12-10 00:05 | 2025-12-05 | INSM | INSMED Inc | SHAROKY MELVIN MD | Director | SELL | $205.01 | 20,000 | $4,100,200 | 243,948 |
| 2025-12-10 00:31 | 2025-12-08 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $478.58 | 22,500 | $10,768,001 | 0 |
| 2025-12-10 00:54 | 2025-12-08 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $478.60 | 21,000 | $10,050,598 | 8,142 |
| 2025-12-10 02:09 | 2025-12-05 | ANIP | Ani Pharmaceuticals Inc. | TANNENBAUM RENEE P | Director | SELL | $81.15 | 1,800 | $146,070 | 25,157 |
| 2025-12-09 02:26 | 2025-12-08 | CNTA | Centessa Pharmaceuticals plc | Accardi Mario Alberto | Officer | OPT+S | $30.00 | 10,000 | $300,000 | 188,801 |
| 2025-12-09 00:36 | 2025-12-04 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | 10% owner | SELL | $10.93 | 21,295 | $232,690 | 161,359 |
| 2025-12-09 00:39 | 2025-12-04 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian BioPharma Inc | 10% owner | SELL | $10.93 | 21,295 | $232,690 | 161,359 |
| 2025-12-09 01:54 | 2025-12-04 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $73.86 | 80,000 | $5,908,472 | 4,558,447 |
| 2025-12-09 00:30 | 2025-12-04 | XOMA | XOMA Royalty Corp | Hughes Owen | Director, Officer | BUY | $25.05 | 100,000 | $2,505,000 | 102,000 |
| 2025-12-08 15:00 | 2025-12-05 | RNXT | RenovoRx, Inc. | Agah Ramtin | Director, Officer | BUY | $0.96 | 10,000 | $9,600 | 766,460 |
| 2025-12-09 01:15 | 2025-11-17 | DMAC | DiaMedica Therapeutics Inc. | STAHLBERG JAN | 10% owner | BUY | $7.19 | 1,061,277 | $7,631,431 | 8,825,742 |
| 2025-12-09 04:05 | 2025-12-08 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Director | BUY | $4.31 | 45,000 | $193,793 | 2,574,739 |
| 2025-12-09 00:30 | 2025-12-04 | CBIO | CRESCENT BIOPHARMA, INC. | Fairmount Funds Management LLC | Director, 10% owner | BUY | $13.41 | 1,360,000 | $18,237,600 | 2,747,866 |
| 2025-12-09 00:07 | 2025-12-04 | RNAC | Cartesian Therapeutics, Inc. | BARABE TIMOTHY C | Director | BUY | $6.86 | 30,000 | $205,797 | 54,366 |
| 2025-12-08 21:21 | 2025-12-02 | GALT | GALECTIN THERAPEUTICS INC | 10X Fund, L.P. | 10% owner | SELL | $5.68 | 162,069 | $920,860 | 5,670,138 |
| 2025-12-09 00:32 | 2025-12-05 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $483.76 | 8,000 | $3,870,057 | 130 |
| 2025-12-09 01:28 | 2025-12-08 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $65.96 | 1,042 | $68,730 | 50,660 |
| 2025-12-06 01:46 | 2025-12-02 | TENX | TENAX THERAPEUTICS, INC. | Rich Stuart | Director, Officer | BUY | $9.12 | 5,000 | $45,622 | 2,500 |
| 2025-12-06 00:08 | 2025-12-05 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Officer | SELL | $20.72 | 144 | $2,984 | 94,729 |
| 2025-12-06 00:09 | 2025-12-05 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Officer | SELL | $20.72 | 880 | $18,234 | 87,510 |
| 2025-12-06 01:01 | 2025-12-03 | RPRX | Royalty Pharma plc | Lloyd George W. | Officer | SELL | $39.77 | 110,000 | $4,375,008 | 110,000 |
| 2025-12-06 00:12 | 2025-12-03 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Tatsis Ourania | Officer | SELL | $449.99 | 4,500 | $2,024,955 | 46,793 |
| 2025-12-06 00:06 | 2025-12-03 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Biller Jonathan | Officer | SELL | $449.00 | 347 | $155,803 | 15,306 |
| 2025-12-06 04:00 | 2025-12-04 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Savitz Ryan | Officer | OPT+S | $45.18 | 20,000 | $903,600 | 0 |
| 2025-12-06 04:49 | 2025-12-04 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | OPT+S | $31.25 | 9,803 | $306,322 | 15,809 |
| 2025-12-06 04:51 | 2025-12-04 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | OPT+S | $31.19 | 5,358 | $167,115 | 19,798 |
| 2025-12-06 02:02 | 2025-12-03 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | Officer | SELL | $18.75 | 31,067 | $582,500 | 277,695 |
| 2025-12-06 04:50 | 2025-12-04 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. MD | Director | OPT+S | $31.13 | 15,001 | $466,959 | 62,554 |
| 2025-12-06 00:21 | 2025-12-03 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | OPT+S | $30.00 | 3,748 | $112,447 | 65,740 |
| 2025-12-06 00:11 | 2025-12-05 | DYN | Dyne Therapeutics, Inc. | Cox John | Director, Officer | SELL | $20.72 | 2,662 | $55,157 | 196,877 |
| 2025-12-06 00:15 | 2025-12-04 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Officer | SELL | $24.71 | 82,997 | $2,050,599 | 954,063 |
| 2025-12-06 00:10 | 2025-12-03 | VRTX | VERTEX PHARMACEUTICALS INC / MA | LEIDEN JEFFREY M | Director, Officer | OPT+S | $449.20 | 63,781 | $28,650,336 | 24,026 |
| 2025-12-06 00:16 | 2025-12-03 | VRTX | VERTEX PHARMACEUTICALS INC / MA | WAGNER CHARLES F JR | Officer | SELL | $456.00 | 14,000 | $6,384,000 | 37,725 |
| 2025-12-06 02:20 | 2025-12-04 | BIOA | BioAge Labs, Inc. | RUBIN PAUL D | Officer | OPT+S | $10.19 | 68,897 | $701,909 | 0 |
| 2025-12-06 02:53 | 2025-12-05 | ENTA | ENANTA PHARMACEUTICALS INC | Capps Kathleen S. | Officer | SELL | $14.23 | 323 | $4,596 | 8,377 |
| 2025-12-06 02:47 | 2025-12-05 | ENTA | ENANTA PHARMACEUTICALS INC | Trout Harry R. III | Officer | SELL | $14.23 | 542 | $7,713 | 16,348 |
| 2025-12-06 02:46 | 2025-12-05 | ENTA | ENANTA PHARMACEUTICALS INC | Rottinghaus Scott T. | Officer | SELL | $14.23 | 798 | $11,356 | 21,792 |
| 2025-12-06 02:45 | 2025-12-05 | ENTA | ENANTA PHARMACEUTICALS INC | Luu Brendan | Officer | SELL | $14.23 | 1,394 | $19,837 | 38,329 |
| 2025-12-06 02:44 | 2025-12-05 | ENTA | ENANTA PHARMACEUTICALS INC | Kieffer Tara Lynn | Officer | SELL | $14.23 | 2,106 | $29,968 | 30,620 |
| 2025-12-06 02:43 | 2025-12-05 | ENTA | ENANTA PHARMACEUTICALS INC | Or Yat Sun | Officer | SELL | $14.23 | 2,390 | $34,010 | 371,392 |
| 2025-12-06 02:41 | 2025-12-05 | ENTA | ENANTA PHARMACEUTICALS INC | Luly Jay R. | Director, Officer | SELL | $14.23 | 4,743 | $67,493 | 858,026 |
| 2025-12-06 00:11 | 2025-12-04 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $205.62 | 10,699 | $2,199,914 | 303,911 |
| 2025-12-06 00:54 | 2025-12-03 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $477.64 | 8,000 | $3,821,130 | 130 |
| 2025-12-06 01:20 | 2025-12-03 | PTCT | PTC THERAPEUTICS, INC. | Reeve Emma | Director | OPT+S | $78.62 | 733 | $57,628 | 6,666 |
| 2025-12-06 01:35 | 2025-12-05 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $65.95 | 52,486 | $3,461,452 | 50,660 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.